Celularity's Cenplacel-L Cell Therapy Gains New Florida Pathway for Investigational Use
CELU sits 44% above its 52-week low of $0.71.
Summary
Celularity's investigational cell therapy, Cenplacel-L, is now available for physician-directed use in Florida under a new state law, creating a unique regulatory pathway outside traditional federal FDA approval. This partnership with Fountain Life establishes one of the first state-level frameworks for allogeneic cellular therapies, potentially accelerating clinical experience and market expansion for Celularity. This positive product development is particularly significant for the micro-cap biotech, which recently disclosed a going concern warning in April. The ability to deploy a lead asset through this new channel could be crucial for the company's financial stability and future development.
At the time of this announcement, CELU was trading at $1.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.5M. The 52-week trading range was $0.71 to $4.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.